Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
J Vasc Surg. 2012 Jun;55(6):1794-800. doi: 10.1016/j.jvs.2012.02.026.
The rate of growth in health care costs in the United States is simply unsustainable. In this economic climate, health care providers will increasingly be asked to justify the existence of health care programs and management strategies on an economic basis. An understanding of cost-effectiveness analyses and its components - direct and indirect costs, quality-adjusted life-years, and incremental cost-effectiveness ratios - is integral to this. We present a primer on the methodology of cost-effectiveness analyses and a review of published cost-effectiveness analyses of vascular surgery interventions with the goal of providing the vascular surgeon with a basic understanding of this topic.
美国医疗保健成本的增长率简直是不可持续的。在这种经济环境下，医疗保健提供者将越来越多地被要求根据经济基础来证明医疗保健计划和管理策略的存在是合理的。了解成本效益分析及其组成部分——直接成本和间接成本、质量调整生命年和增量成本效益比——是必不可少的。我们介绍了成本效益分析方法的基础，并回顾了已发表的血管外科学干预措施的成本效益分析，旨在使血管外科医生对这一主题有一个基本的了解。
